Gus Alva, MD, DFAPA

Panelists discuss how integrating xanomeline/trospium into clinical practice may expand safe and effective treatment options.

Panelists discuss how the muscarinic pathway of xanomeline/trospium offers a safer, nondopaminergic approach to schizophrenia care.

Panelists discuss how balancing adverse-effect management with adherence optimization drives effective therapy transitions.

Panelists discuss how thoughtful sequencing of antipsychotics enhances adherence, safety, and long-term efficacy.

Panelists discuss how evidence-based, patient-tailored guideline adherence enhances long-term schizophrenia outcomes.

Panelists discuss how addressing social and structural barriers is essential to achieving equitable outcomes in schizophrenia care.

Panelists discuss how relapse intensifies clinical and economic burdens, reinforcing the need for adherence and prevention-focused care.

Panelists discuss how early and sustained intervention can reshape schizophrenia’s chronic course and improve long-term quality of life.

Panelists discuss how stigma and symptom overlap delay accurate schizophrenia diagnosis and how early intervention can transform outcomes.

Panelists discuss how genetics, environment, and substance use interplay to shape schizophrenia risk and guide preventive care.

Panelists discuss how understanding and managing the full range of schizophrenia symptoms is key to improving long-term patient outcomes.

Panelists discuss how schizophrenia’s immense personal and financial burden calls for early, integrated, and sustained care strategies.